A series of small-size polyethylenimine (PEI)-conjugated pluronic polycarbamates (PCMs) have been investigated for the ability to modulate the delivery of 2 0 -O-methyl phosphorothioate RNA (2 0 -OMePS) in vitro and in dystrophic mdx mice. The PCMs retain strong binding capacity to negatively charged oligomer as demonstrated by agarose gel retardation assay, with the formation of condensed polymer/oligomer complexes at a wide-range weight ratio from 1:1 to 20:1. The condensed polymer/oligomer complexes form 100-300 nm nanoparticles. Exon-skipping effect of 2 0 -OMePS was dramatically enhanced with the use of the most effective PCMs in comparison with 2 0 -OMePS alone in both cell culture and in vivo, respectively. More importantly, the effective PCMs, especially those composed of moderate size (2k-5kDa) and intermediate hydrophilic-lipophilic balance (7-23) of pluronics, enhanced exon-skipping of 2 0 -OMePS with low toxicity as compared with Lipofectamine-2000 in vitro or PEI 25k in vivo. The variability of individual PCM for delivery of antisense oligomer and plasmid DNA indicate the complexity of interaction between polymer and their cargos. Our data demonstrate the potential of PCMs to mediate delivery of modified antisense oligonucleotides to the muscle for treating muscular dystrophy or other appropriate myodegenerative diseases.
INTRODUCTION
Antisense oligonucleotide (AO)-mediated therapy (antisense therapy) has shown great potential for treating diseases, including viral infections and cancers, by knocking down specific genes, and genetic disorders such as Duchenne muscular dystrophy (DMD). 1, 2 DMD is caused by frame-shift and non-sense mutations, leading to loss of dystrophin production, which in turn weakens muscle structure and function. Antisense therapy for DMD uses specific oligonucleotides to correct the out-of-frame transcripts to restore the expression of dystrophin through exon-skipping. Therapeutic effects of exon-skipping for DMD have been demonstrated in both animal models and in phase I/II clinical trials. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Achieving high levels of dystrophin expression, 420% normal levels in body-wide muscles is considered to be necessary for significant therapeutic effect in clinics. However, this level of efficiency will be difficult to achieve with phosphorodiamidate morpholino oligomer (PMO) or 2 0 -O-methyl phosphorothioate RNA (2 0 -OMePS) chemistries currently undertaken in clinical trials. Ongoing clinic trials with both 2 0 -OMePS and PMO targeting dystrophin exon 51 have reported functional benefit to the patients. However, the limited dosage and delivery efficiency might only be able to provide reduced rate but not the prevention of disease progression. Furthermore, the dosage of weekly 50 mg kg À 1 PMO is already cost inhibitive for most patients as a life-long therapy. Therefore, increasing delivery efficiency is one key for achieving long-term success of the therapy. This is also important for 2 0 -OMePS oligomers, as 6 mg kg À 1 weekly administration regime used in ongoing trials by GlaxoSmithKline has already reported clear renal side effect. 6 Despite the fact that 2 0 -OMePS oligomers are resistant to nuclease degradation and stable in biological system with the phosphorothiolate backbone, only a small proportion of 2 0 -OMePS delivered systemically is taken up into the targeted muscle cells. These facts suggest that improving delivery efficiency will be the most likely option for further enhancement of therapeutic value using the 2 0 -OMePS chemistry. 6, 15, 16 Over the past decade, synthetic polymers have been widely studied as non-virus vectors for gene and drug delivery. However, very few polymers have been demonstrated with the capability of enhancing gene/AO delivery to treat systemic muscle disease. Among them is the amphiphilic polymer, such as pluronics and tetronics, which are composed of hydrophilic ethylene oxide and hydrophobic propylene oxide blocks. Several studies have reported promising results with this kind of polymer as effective carriers for plasmid DNA (pDNA) or AO to muscles through local injection. [17] [18] [19] [20] [21] [22] However, systemic delivery effect has been limited due to poor affinity between the non-ionic polymers and chargeneutral PMO, and negatively charged 2 0 -OMePS or pDNA. A simple formulation of mixing these polymers with charge-neutral PMO or negatively charged 2 0 -OMePS will likely lead to a quick separation of the components on introduction to the circulatory system. PEI forms aggregates and these are cleared quickly by the liver through circulation. These, together with the strong positive charge, are directly associated with their high cytotoxicity, leading to difficulty for the use in clinical trials. Alternatively, the modification of low-Mw PEI has been reported as a nucleotide carrier and has shown some effect in gene/AO delivery. 8, 13, 25, 26 For example, the enhanced exon-skipping of 2 0 -OMePS treated with PEG550-PEI2000 copolymer in skeletal muscle has been reported, but the improvement remains limited, which are likely attributable to the hydrophilic property of the polymer and limited interaction between the polymer/ 2 0 -OMePS complex and cell membrane. We have recently developed a series of amphiphilic pluroniclow-Mw PEI polycarbamates (PCMs) and investigated their ability to deliver pDNA and uncharged PMO in vitro and in vivo of dystrophic mdx mice. 27, 28 The results showed the PCMs were able to enhance PMO-mediated exon-skipping in vitro and in mdx mice. 28 Furthermore, nearly all PCMs bind and condense pDNA effectively into nano-sized particles and produced significantly higher gene delivery efficacy and less cytotoxicity as compared with PEI 25k in both C2C12 myoblasts and in vivo. 27 2 0 -OMePS oligomers are chemically very similar to the pDNA in structure with negative charge. We therefore hypothesize that PCMs could also enhance the delivery of 2 0 -OMePS oligomers. Here we applied PCM series for the delivery of 2 0 -OMePS targeting exon 23 of the dystrophin gene and demonstrated that these cationic amphiphilic polymers increased exon-skipping efficiency considerably in cell culture and in mdx mice. The most effective PCMs were those composed of pluronics of moderate size (2k-5kDa) and intermediate hydrophilic-lipophilic balance (HLB ¼ 12-23). The improved transgene efficiency with low toxicity indicates the potential of the PCMs as antisense oligomer delivery vector for muscular dystrophy.
RESULTS

Synthesis and characterization of PCM copolymers
These PCM polymers were synthesized from pluronic activated by 1,1 0 -carbonyldiimidazole followed by reaction with excess of low-Mw PEI (0.8k, 1.2k). 27 The nomenclature and composition of the cationic amphiphilic polymers are presented in the Supplementary Information.
Characterization of polymer/oligomer polyplexes To determine the interaction between PCM polymers and oligonucleotide (oligomer), we evaluated the mixture of the two components at various ratios using agarose gel electrophoresis. Electrostatic interaction between the positively charged PCMs and the negatively charged oligomers leads to subsequent condensation and polyplex formation, resulting in decreased migration within the gel. As illustrated in Figure 1 , nearly all PCM polymers used with oligomers at ratios 2:1 or higher showed high capacity to bind oligomers, resulting in condensed and/or chargeneutralized oligomers as indicated by the shifting of the ethidium bromide-stained bands toward significantly higher Mw position, most of them within the loading wells in the gel. These results are consistent with the expectation that negative charges on oligomers are progressively neutralized by the positive charges on PCM as the ratio of PCM/oligomer increased. Some complexes, such as PCM-04/07/09, migrated slightly toward the anode when ratios of PCM/oligomer was 5:1-20:1, suggesting that the complex became positively charged. PCMs composed of smaller-size PEI 0.8k, such as PCM-02/03/08/13 showed weaker binding capacity to oligomer at low weight ratio (polymer/oligomerp2). Similarly, PCM-06 composed of larger-size pluronic F127 (Mw, 12.6k) and PEI 1.2k also showed weak binding capacity to oligomer at low feed ratio (polymer/oligomerp2) compared with other moderate-sized pluronics. Again, the results suggest that the proportion of PEI component within PCMs determines overall charge state of the complex. However, the particle size of the complex could not be determined by the gel analysis.
The polymer/oligomer complex size is important for effective gene transfer, with nano-sized particles considered to be optimal. 22, 23 We therefore examined the complex of PCM polymers with oligomers by dynamic light scattering (DLS). All the PCM polymers condensed the oligomers into highly homogenous hydrodynamic particles with diameters below 300 nm at a polymer/oligomer ratio of 2-10. The particle of the PCM/oligomer at a ratio of 20 was more heterogenous with size reaching 4400 nm ( Figure 2a illustrates the particles with a polymer/ oligomer ratio of 5). This was consistent with the results from transmission electron microscopy (TEM) examination. As illustrated in Figure 2b , the PCM/oligomer nanoparticles were well defined and fairly uniformly distributed with sizes below 100 nm at a representative w/w ratio of 5. The clearly smaller particle size under TEM in comparison with that from DLS analysis was most likely the result of TEM processing, which required the samples to be dried, causing reduction in particle size. The DLS analysis showed that the condensed nanoparticles possessed moderate surface charges. As expected, the average zeta potentials of polyplexes were from À 23.2 to 17.3 mV (the polymer/oligomer weight ratio of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , much lower than that of PEI 25k. In contrast, the physically blended pluronic and PEI mixture with the same amount of oligomers produced bigger particle sizes ranging from 400 to 850 nm (data not shown).
PCM-medicated 2 0 -OMePS delivery in vitro
We evaluated the potential of PCM polymers for enhancing exonskipping effect of 2 0 -OMePS in the C2C12E50 cells expressing a green fluorescent protein (GFP) reporter transgene disrupted by the insertion of the human dystrophin exon 50. 4, 28 The tested doses were based on the cytotoxicity data published previously. 28 Less than 15% of cell death was observed with PCM-02, PCM-03, PCM-05, PCM-06, PCM-07 and PCM-08 at a high dose of 20 mg ml À 1 . Therefore, a maximum of 40 mg ml À 1 polymer was used for the delivery of 2 0 -OMePS in this study. The cells were treated with 2 mg 2 0 -OMePSE50 (5 0 -AACUUCCUCUUUAACAGAAAA GCAUAC-3 0 ) targeting human dystrophin exon 50 and formulated with the polymers at four different doses 2, 5, 10 and 20 mg in 500 ml medium. The results showed the use of all PCMs enhanced GFP expression, indicating improved delivery efficiency when compared with 2 0 -OMePSE50 alone. GFP expression reached maximum when PCM polymers were used at 5 or 10 mg, By fluorescence-activated cell sorting analysis, only o1% cells were gauged as GFP positive when treated with 2 0 -OMePSE50 alone. However, GFP-positive cells reached 57-83% when 5 or 10 mg amphiphilic PCMs (such as PCM-01, PCM-02, PCM-04, PCM-05 and PCM-09) were complexed with 2 0 -OMePSE50. These levels of GFP expression with amphiphilic PCMs were significantly higher than that (o6%) achieved with hydrophilic polymers (PCM-13 and PCM-14). Toxicity of 2 0 -OMePS formulated with most PCMs remained similar to that observed with 2 0 -OMePS alone. However, cell viability with PCM-09 (10 mg) was clearly reduced (to B65%), although still higher than that of PEI 25k (2 mg) or LF-2000 (4 mg) treated controls.
To directly compare the efficiency of PCMs for delivery of pDNA and 2
0 -OMePS, we tested the most effective PCM-04 (previously reported for pDNA delivery) 27 with optimal dosage and under the same culture condition of C2C12 myoblasts and GFPE50 reporter cell line (Figure 4) . The results showed that PCM-04 produced clearly higher delivery efficiency for both 2 0 -OMePS and pDNA than LF-2000 and PEI 25K. The high efficiency of PCM-04 for negatively charged nucleotide sequences was further confirmed by the delivery of a Cy3-labeled RNA oligomer (24mer). We also compared the delivery efficiency of PMO with PCM-04 and Endoporter (one commercial agent for PMO delivery designed by Gene Tools, Philomath, OR, USA). Again, PCM-04 produced higher levels of GFP induction than Endoporter, much higher than PEI 25k. These results indicate that PCM-04 enhances delivery for both negatively charged or non-charged short oligonucleotides and larger pDNA, further suggesting the importance of amphiphilic nature for delivery of nucleic acids and their derivatives in muscle cell. In contrast, LF-2000 gave high delivery efficiency with pDNA but low efficiency with shorter oligomer. Similarly, PEI 25k showed relatively high efficiency for pDNA delivery but with reduced efficiency for PMO and 2 0 -OMePS. This is consistent with previous publications that high-Mw PEI is less efficient in delivery of short interfering RNA and single-stranded AOs. 29, 30 One probable explanation is the weak interaction of high-Mw PEI with short oligonucleotides, resulting in earlier dissociation of the polyplex upon contact with polyanions in the environment.
PCM-mediated 2 0 -OMePS delivery in vivo
In order to evaluate the ability of the PCMs to enhance exonskipping in vivo, 2 mg of 2 0 -OMePSE23 was formulated with each of the polymers and administrated by intramuscular (i.m.) injection to the tibialis anterior (TA) muscles of the mdx mice aged 4-5 weeks. The treated muscles were examined 2 weeks after the injections. Immunohistochemistry showed that 2 0 -OMePSE23 alone induced a maximum of 33±9 dystrophin-positive fibers in one cross-section of the treated muscle. The numbers of dystrophin-positive fibers increased up to three to eight folds in the muscles treated with 2 0 -OMePSE23 in combination with 5 mg PCMs. In particular, dystrophin-positive fibers were counted up to 211 ± 14, 141 ± 26, 182 ± 19, 227 ± 32 and 241 ± 56 in muscles treated with 2 0 -OMePSE23 in combination with PCM-01, PCM-02, PCM-05, PCM-08 and PCM-09, respectively. In contrast, PEI 25k produced 52±7 positive fibers. Consistent with the efficiency in exon-skipping observed in cell culture, the numbers of dystrophin-positive fibers were low with PCM-03, PCM-13 and PCM-14 ( Figure 5 ). Hematoxylin and eosin staining revealed no signs of increased inflammation or fiber necrosis compared with untreated mdx muscle, coinciding with our previously results for pDNA and PMO delivery that these polymers were not cytotoxic at the doses used.
27,28
DISCUSSION
In this study, we evaluated PCM polymers composed of pluronic and low-Mw PEI for the delivery of 2 0 -OMePS oligomers. The results suggest that PCMs with optimized combination of these two components can significantly enhance the delivery efficiency with limited toxicity both in vitro and in vivo.
The charge status of polymers is considered important for effective gene/oligomer delivery in vitro and in vivo, 31,32 which largely determines the interaction between not only the polymer and its cargo but also the polymer and its environment during their journey to the inside of targeted cells. The charge status is also critical for the toxicity, thus the application of the polymers. As expected, all PCM amphiphilic cationic polymers showed strong binding ability to the negatively charged 2 0 -OMePS oligomer and formed complexes via electrostatic interaction at the PCM/oligomer ratios for effective delivery. As pluronics alone do not bind the oligomers, this interaction is certainly attributed to the positive charge of PEI. Consistently, the binding strength relies on the PEI content within amphiphilic PCMs, with PCMs such as PCM-01/04/05/07/08/09/10, containing higher amount of PEI exhibiting stronger interaction with 2 0 -OMePS oligomers, whereas binding capacity decreases for PCMs composed of smaller-size PEI 0.8k (such as PCM-02/03/13) or large pluronic (such as F127 in PCM-03/06). In addition, the binding also associated with the HLB; moderate amphiphilic PCMs (such as PCM-01/04/05/07/08/09/10) gave better binding with 2 0 -OMePS than more hydrophilic PCMs (such as the PCM-03/06/13; Figure 1 ), which indicates the lipophilic interation existed between amphiphilic polymer and oligomer. More importantly, the content of PEI is not directly related to the capacity of delivery efficiency both in vitro and in vivo. As both PCM-01 and PCM-02 showed higher delivery efficiency in vitro, but has considerable difference in PEI content, it is therefore apparent that the type of pluronic within the PCMs is more important for the delivery efficiency. All PCMs containing moderate HLB balance (12-23) of pluronics, such as L64, P85, L35 and L44, exhibited higher delivery efficiency for PMO and 2 0 -OMePS, whereas the PCMs owning more hydrophilic pluronic F127 or more lipophilic P123 showed lower delivery efficiency. This is further confirmed with the lower transfection efficiency in PCM-13/14, which are composed of hydrophilic PEG-6000. On the other hand, the presence of hydrophobic groups may increase oligomer delivery by enhancing the interaction between PCM polymers and cell surface molecules. However, high-degree hydrophobicity of pluronics within the PCMs is associated with higher toxicity, and thus the reduced delivery efficiency. Clearly, a better understanding of the complex interaction within the PCM polymer and among PCM, oligomer and cell surface molecules could further improve our optimal design of polymers for higher efficacy and lower toxicity. Overall, these results suggest that the ratios between these two components and HLB are critical factors for enhancing efficiency in oligomer delivery. 
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It has been reported that polyplexes with appropriate size and better distribution are associated with improved efficiency in gene transfection. 31 Nearly all new PCM polymers are able to condense 2 0 -OMePS oligomer into highly homogenous nanoparticles below 300 nm. In contrast, a physical blend of the pluronic and PEI with the same ratio of oligomers produced heterogeneous and large aggregates. As the pluronics are amphiphilic, it is likely that their stable presence within PCM contributes to the formation and desirable sizes of the particles by preventing the formation of PEI/oligomer aggregation. 20, [33] [34] [35] Our results also show that the PCM-01/02/04/05 with higher delivery efficiency have the polyplex sizes p200 nm at the tested doses, whereas the ones with larger particle size (such as PCM-13/06/10/11) have a lower delivery efficiency both in vitro and in vivo. It is thus possible that optimized composition of pluronics and PEI within PCMs, and moderate HLB as well as condensed polyplex particle, are contributing to better delivery. Pluronic-PEI conjugates (PCMs) differ from a simple mixture of these two compositions. It reduces charge density of PEI by eliminating primary amines of PEI through the carbamate link. The decrease of primary amines could also explain the reduced toxicity of the PCMs when compared with PEI components of the same concentration.
The efficiency of individual PCMs for the delivery of 2 0 -OMePS is not always consistent with that of plasmid transgenes. PCM-01 and PCM-02 showed much higher delivery efficiency for 2 0 -OMePS than for pDNA both in vitro and in vivo, whereas the two cargos are similar in structure and in surface charge. 27 The most obvious difference is the size of the two cargos. One possibility is the difference in stability of the complex. The smaller oligomers are likely to form more stable complex with moderate-sized polymers, particularly when the complex is present within a biological system and interacts with serum and many other cellular components. Another possible factor involved is the relatively hydrophobic nature of 2 0 -OMePS when compared with the pDNA. This creates unique hydrophobic interactions between the PCM and 2 0 -OMePS, thus creating a more stable complex in primarily hydrophilic environments both in vitro and in vivo. This may also partly explain the reason for the efficient delivery of 2 0 -OMePS and PMO with PCMs, such as PCM-04 in vitro. Efficiency of PCMs for PMO delivery in vivo is in the following order: PCM-04/ 054PCM-01/02/11/124PCM-06/07/084PCM-064PCM-03/13/14. This indicates that the efficiency might very well be related to the hydrophobic interaction between the polymer and the neutral PMO; meanwhile, efficiency of PCMs for 2 0 -OMePS delivery in vivo is the following order: PCM-08/094PCM-014PCM-054PCM-02/ 04/11/12/10/074PCM-064PCM-03/13/14, which showed that the delivery efficiency depends on both the hydrophobic interaction and electrostatic interaction relative to the PEI content and Mw of PCMs. Therefore, it remains necessary to optimize the potential PCMs for delivery of different types of cargos individually for maximal efficiency and minimal toxicity. Nevertheless, the versatility of the PCM polymers highlights the advantage of this class of cationic amphiphilc polymers with the potential for further development to clinical applications of gene and oligonucleotide therapies. 0 -OMePSE50/ PMOE50 in C2C12E50 cell line, respectively. The doses of delivery reagents and pDNA or oligomer are formulated in 500 ml culture medium. C2C12E50 is C2C12 cell line expressing reporter GFP with its expression disrupted by the insertion of human dystrophin exon 50.
MATERIALS AND METHODS Materials
PCMs were synthesized as published previously. 27 Branched poly(ethyleneimine) PEI, acetonitrile and ethanol were purchased from Sigma-Aldrich (St Louis, MO, USA); pEGFP(4.7 kb) was obtained from BD Biosciences (Franklin Lakes, NJ, USA); cell culture media Dulbecco's modified Eagle's medium, penicillin-streptomycin, fetal bovine serum, l-glutamine, HEPES buffer solution (1 M), and MTS (3-(4,5-dimethylthiazol -2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) were purchased from GIBCO, Invitrogen Corp. (Carlsbad, CA, USA). All other chemicals were reagent grade. 2 0 -OMePSE50 (5 0 -AACUUCCUCUUUAACA GAAAAGCAUAC-3 0 ) and 2 0 -OMePSE23 (5 0 -GGCCAAACCUCGGCUUACCU-3 0 ) were from GenScript (Piscataway, NJ, USA). GFP reporter C2C12 myoblasts were grown in Dulbecco's modified Eagle's medium and maintained at 37 1C in a humidified 10% CO 2 incubator. Cells (5 Â 10 4 ) per well were plated in a 24-well plate in 0.5 ml Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. After 24 h, the cell culture medium was replaced with serum-free medium before addition of polymer/oligomer polyplexes formulated with varying ratio of polymer/ oligomer. The structures of the synthesized polymers were confirmed through 1 H-NMR (JEOL ECA-500 nuclear magnetic resonance spectrometer, JEOL USA Inc., Peabody, MA, USA). The polyplex particle size and surface potential were measured by TEM and DLS by using the ZetaPALS Zeta Potential Analyzer 90 Plus/BI-MAS (Brookhaven Instruments Corporation, Holtsville, NY, USA) option at 25 1C, with a fixed angle of 901. The cytotoxicity was evaluated using the MTS assay. Transfection efficiencies were estimated qualitatively and quantitatively using Olympus IX71 and BX51 microscopy (Olympus, America Inc., Melville, NY, USA) and flow cytometry (BD FACScalibur, BD Biosciences, Franklin Lakes, NJ, USA) respectively.
Complexation study of polymer/oligomer All polymer/oligomer complexes were freshly prepared before use by gentle vortexing of oligomer and polymer solutions at various polymer/ oligomer weight ratios (from 1:1, 2:1, 5:1, 10:1 to 20:1 with 1 mg oligomer used). The complexes were incubated at room temperature for 30 min in 24 ml volume, including loading dye mixture, and loaded on 1% agarose gel with ethidium bromide (0.1 mg ml À 1 ). Gels were run with tris-acetate buffer (100 V, 40 min) and analyzed on UV illuminator to assess the location of the oligomers.
Particle size, zeta potential and morphology analysis
The hydrodynamic diameters of polymer/oligomer complexes were determined by DLS. Two milliliters of polyplex solution containing 5 mg of oligomer was prepared at various weight ratios (polymer/ oligomer ¼ 1:1-20:1). After 30 min incubation, polyplex sizes were measured by photon correlation spectroscopy using Zetaplu Zeta Potential Analyzer equipped with a 15-mV solid-state laser operated at a wavelength of 635 nm. Scattered light was detected at a 901 measurement angle. The refractive index (1.33) and viscosity (0.89) of 0.9% sodium chloride were used at 25 1C. The zeta potentials were also measured using the same instrument with a different software. The default sampling time was used and potential values are presented as the average of six runs.
Morphologies of the polymer/oligomer complexes were analyzed using TEM (Phillips CM-10, PhilipsElectronics North America corp., Andover, MA, USA). The samples were prepared using negative staining with 1% phosphotungstic acid. Briefly, one drop of polymer/oligomer complex solution was placed on a formvar and carbon-coated carbon grid (Electron Microscopy Sciences, Hatfield, PA, USA) for 1 h, and the grid was blotted dry. Samples were then stained for 3 min, the grids blot dried again and samples were analyzed at 60 kV. Digital images were captured with a digital camera system from 4 pi Analysis (Durham, NC, USA).
In vitro transfection
The C2C12 E50 cell has a human dystrophin exon 50 sequence placed inside the coding sequence of the GFP gene under control of an actin promoter. Upon specific AO delivery, the human dystrophin exon 50 sequence is spliced out and the GFP coding sequence rejoined back in frame.
C2C12 or C2C12E50 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and maintained at 37 1C and 10% CO 2 in a humidified incubator. Cells (5 Â 10 4 ) per well were seeded in a 24-well plate in 500 ml medium and allowed to reach 70-80% confluence before transfection experiments. Cell culture medium was replaced with serum-free medium before addition of polymer/pDNA, oligomer or 2 0 -OMePSE50 cargos formulated with varying weight ratio of polymer/cargo. PEI 25k and LF-2000 were used as control for delivery. Transfection efficiencies were measured by visualization using an Olympus IX71 fluorescent microscope. Digital images were taken using the Olympus DP Controller and DP Manager software (DP 70-BSW software; Olympus America Inc., Melville, NY, USA), and also examined using flow cytometry to quantitatively gauge the GFP expression level. Cells were washed with phosphate-buffered saline (1 Â ) and released from culture vessel with 0.05% Trypsin-EDTA, neutralized by fetal bovine serum, pelleted by centrifugation and then resuspended in 1 ml phosphate-buffered saline. Samples were run on a FACSCalibur flow cytometer. Cells (5 Â 10 3 ) were counted and analyzed with CellQuest Pro software package (BD Bioscience, San Jose, CA, USA).
In vivo delivery and antibody immunohistochemistry
For in vivo testing, mdx mice aged 4-5 weeks were used, from which four muscles were examined for each experimental group. Experimental protocols were conducted as approved by the Institutional Animal Care and Use Committee, Carolinas Medical Center. The 2 0 -OMePSE23 ( þ 02-18; 5 0 -GGCCAAACCUCGGCUUACCU-3 0 ) targeting the boundary sequences of exon and intron 23 of mouse dystrophin gene were used. For intramuscular injections, 2 mg 2 0 -OMePSE23 with or without polymer was used in saline suspensions for each tibialis anterior muscle. The mice were killed 2 weeks after injection and tibialis anterior muscles were collected for examination.
Serial sections were cut from the treated tibialis anterior muscles together with control muscles. The sections were stained with rabbit polyclonal antibody P7 for the detection of dystrophin protein as described previously. 5 Polyclonal antibodies were detected by Alexa 594 goat anti-rabbit IgG secondary antibody (Invitrogen, Carlsbad, CA, USA).
